The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen has finalized a licensing agreement with Roots Pharmaceutical for its OCU400 gene therapy in the MENA region. The deal includes up to 4 million dollars in upfront and early development milestone payments, with potential sales milestones of 255 million dollars and a 22 percent royalty on net sales.
The partnership is set to advance the global commercialization of OCU400, expanding Ocugen's reach into new international markets.
View post on X Loading...
Ocugen previously gained provisional approval and priority designation for OCU400 gene therapy in the Bahamas, advancing regulatory progress in that market via earlier filings. The company also launched a commercial Expanded Access Program in the Bahamas to provide OCU400 for retinitis pigmentosa, according to company announcements. These steps laid the groundwork for Ocugen’s continued international expansion.